Phacilitate Leaders World

Speakers

Loading
Michael Covington

Michael Covington

Principal CMC Regulatory Policy and Strategy, Juno Therapeutics, Inc
United States

Michael is a dedicated professional with over 25 years of Biotechnology, Cellular, and Gene Therapy experience in areas including Regulatory Affairs, Regulatory Compliance, Quality, Validation, and Manufacturing.   He is a leader with demonstrated success in supporting important commercial recombinant protein therapeutics including Epogen (epoetin alfa), Aranesp (darbepoetin alfa), Neupogen (G-CSF), and Kineret (IL-1ra).   Additional experience has been garnered in supporting innovative autologous cellular immunotherapies including Provenge (Commercial, CD54 antigen presenting cells), Nuevenge (Phase II, CD54 antigen presenting cells), and autologous genetically modified T cell immunotherapies such as CD19 CAR T cells.  Michael has worked with Monsanto, Amgen, Dendreon, and is currently working with Juno Therapeutics.

Testimonials
  • Real thinking forward combining experts in the field from manufacturing, regulatory and value vision” – “great network with strong experience and sharing risks & opportunities
    Anne-Virginie Eggimann
    bluebird bio
  • Great program, great people, great venue.
    Klaus Kühlcke
    EUFETS GmbH
  • Dynamic, interesting and highly interactive event that promotes exchange and networking in highly specialized field of gene therapy.
    Nathalie Clement
    Powell Gene Therapy Center, University of Florida
  • Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field.
    Dr James Trager
    Dendreon
  • It was all business. I’ve never been to an event where over 80% of the conversations I had were constructive to my business objectives.
    Kurt Gielen
    Chemelot Campus B.V.
  • Great way to expand network with global experts in cell and gene therapy who are facing similar challenges.
    Steven Goodman
    GSK